NCT03254732View on ClinicalTrials.gov

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

PHASE1TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 14, 2017

Primary Completion Date

May 7, 2019

Study Completion Date

February 25, 2020

Conditions
Advanced Solid Cancers
Interventions
DRUG

ADI PEG20

ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.

DRUG

Pembrolizumab

Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.

Trial Locations (1)

704

Facility National Cheng Kung University, Tainan City

Sponsors

Lead Sponsor

Polaris Group
All Listed Sponsors
lead

Polaris Group

INDUSTRY

NCT03254732 - Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers | Biotech Hunter | Biotech Hunter